Scientists Engineer Insulin-Producing Cells to Evade the Immune System

In Type 1 diabetes, the immune system mistakenly attacks the body's own insulin-producing beta cells. Researchers have long known that much of this attack is aimed at a specific part of insulin called the signal peptide—essentially a molecular shipping label that guides newly made insulin through the cell.

This discovery creates a challenge: any cell transplant therapy would need to either hide from the immune system entirely or somehow protect beta cells without turning off the immune response globally, which carries serious risks.

Scientists at the University of Washington and collaborating institutions tested a creative solution: what if they kept the insulin itself but changed its signal peptide to something the immune system wouldn't recognize?

The team engineered human beta cells with a different signal peptide—borrowed from a hormone called chromogranin-A. This swap allowed the cells to produce insulin with a disguised identity, one that autoreactive T cells no longer targeted.

The critical question was whether this molecular disguise would compromise insulin function. Testing showed it did not.

Cells with the engineered signal peptide successfully synthesized insulin, processed it correctly, and secreted it in healthy ratios. The secreted insulin remained fully active—capable of doing its job of lowering blood glucose. The modification didn't harm the cells themselves; they maintained their identity and function without signs of cellular stress.

This proof-of-concept study offers a targeted alternative to systemic immunosuppression, which requires people to take drugs that weaken their entire immune response and carry significant long-term risks.

The researchers envision this approach being used with stem-cell-derived therapies: growing beta cells from a patient's own stem cells, engineering them to evade autoimmune attack, and then transplanting them back. Because the cells would be hidden from the immune system, they might survive and function without immunosuppressive medication.

This work remains in the laboratory stage. The next steps would involve testing the engineered cells in animal models and eventually human trials. Much more research is needed before this could become a treatment option.

Source: Cell reports. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.